Orient Of Taiwan To Skip Phase II To Final-Stage Trial Of ADHD Drug
This article was originally published in PharmAsia News
Executive Summary
Taiwan's Orient Pharma said it plans to skip Phase II clinical trials of its attention deficit hyperactivity disorder drug and go directly to Phase III tests so it can launch by the end of 2016.